Drug Trial Radar · NCT06529822
Personalized Cancer Vaccine (PCV) Strategy in Patients With Solid Tumors and Molecular Residual Disease
Last checked: Nov 20, 2026Latest source record: Sep 21, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
64
Planned (sponsor's estimate)
Start
Mar 20, 2025
Primary completion
Jan 31, 2030
Study completion Jun 30, 2034
Sponsor
- Lead sponsor
- Washington University School of MedicineAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- Collaborators
- Natera, Inc.
- First posted
- Jul 31, 2024
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Non randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is a phase 1 clinical trial to evaluate the safety, feasibility and immunogenicity of a personalized cancer vaccine strategy in patients with solid tumors and molecular residual disease. The hypothesis of the trial is that synthetic long peptide personalized cancer vaccines will be safe and capable of generating measurable neoantigen-specific T-cell responses enabling ctDNA clearance. The personalized cancer vaccines are composed of synthetic long peptides corresponding to prioritized cancer neoantigens and will be co-administered with poly-ICLC.
Conditions
- Muscle-Invasive Bladder Carcinoma
- Gastroesophageal Adenocarcinoma
- Melanoma
- Non-small Cell Lung Cancer
Interventions
Synthetic long peptide personalized cancer vaccineBiological
Neoantigen vaccines will be provided on a patient-specific basis
Poly ICLCDrug
Poly-ICLC will be supplied by Oncovir, Inc.
Signatera or Altera testingDevice
Testing used to identify and prioritize neoantigens.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Safety as measured by treatment-emergent adverse events (TEAEs)Time frame: From 1st vaccine dose through 30 days following last dose of vaccine (estimated to be 13 months)
- Safety as measured by treatment-related adverse events (TRAEs)Time frame: From 1st vaccine dose through 30 days following last dose of vaccine (estimated to be 13 months)
- Safety as measured by serious adverse events (SAEs)Time frame: From 1st vaccine dose through 30 days following last dose of vaccine (estimated to be 13 months)
- Feasibility as measured by the success of enrolling patients with molecular residual diseaseTime frame: Through 30 months
- Feasibility as measured by the expected time frame for vaccine creationTime frame: Through 24 weeks
- Feasibility as measured by the rate of successful vaccine deliveryTime frame: Through 1st vaccine dose (estimated to be 24 weeks)
Locations
3 sites in 1 country. Site status is shown where the registry gives one.
AdventHealth
Orlando, Florida · Not yet recruiting
Washington University School of Medicine
St Louis, Missouri · Recruiting
Ohio State University
Columbus, Ohio · Not yet recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.